A London clinic has become the first in Europe to roll out two Alzheimer’s wonder drugs privately after they were rejected ...

One described the approval of lecanemab as “no panacea” for patients, for example, while another went as far as to suggest that, in their eyes, donanemab offered “no net benefit” at all.

BTIG analyst Thomas Shrader has maintained their neutral stance on BIIB stock, giving a Hold rating on January 23.Invest with Confidence: ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

Japanese pharmaceutical company Eisai Co. and U.S. firm Biogen Inc. said Monday that a jointly developed Alzheimer's drug has ...

The new study found anti-inflammatory drugs, such as ibuprofen, as well as antibiotics, antivirals and vaccinations, were associated with a lower risk of developing dementia ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

Global Alzheimer's Disease Therapeutics Market Size is expected to be worth around USD 30.8 Billion by 2033 from USD 5.5 Billion in 2023.

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Research based on more than 130 million people found a number of existing medications that could help in the fight against dementia.